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Several studies from Southern Africa report a high risk of tuberculosis among individuals 
who have been previously treated for the disease compared to those never treated before [1–
5]. In high-burden settings, recurrent tuberculosis may affect large numbers of individuals 
even after successful treatment, with exogenous reinfection as an important underlying 
mechanism [2–4]. For example, in Cape Town, a city with a high incidence of tuberculosis 
in South Africa, previously treated individuals constitute one-third of the burden of notified 
tuberculosis [6].
The impact of recurrent disease on tuberculosis epidemics in Southern Africa is not well 
understood. In particular, there is limited knowledge about the extent to which previously 
treated people contribute to the pool of undiagnosed prevalent tuberculosis and transmission 
in high-burden settings. Two prevalence surveys in Zambia [7] and Zimbabwe [8] reported 
that previous treatment was strongly associated with prevalent tuberculosis among HIV-
uninfected individuals. Ten out of 18 smear-positive tuberculosis cases detected in a 
prevalence survey in a South African suburban setting had a history of previous treatment 
[9], consistent with the hypothesis that previously treated people contribute considerably to 
tuberculosis prevalence and transmission in this setting.
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Better quantification of prevalent tuberculosis by treatment history can inform estimates of 
the importance of previously treated individuals for the dynamics of tuberculosis epidemics 
and help determine if specific interventions targeted to this risk group could accelerate 
tuberculosis control. We therefore aimed to investigate, across 24 African communities, how 
common a history of previous treatment was, whether the prevalence of tuberculosis differed 
by history of previous treatment, and to what extent previously treated individuals 
contributed to the overall prevalent tuberculosis burden.
We analysed data from tuberculosis prevalence surveys conducted in 2010 as the primary 
outcome measure of the Zambia South Africa Tuberculosis and AIDS Reduction 
(ZAMSTAR) study, a large community-based intervention trial in 24 tuberculosis and HIV 
high-burden communities, 16 in Zambia and 8 in South Africa (Western Cape Province) [10, 
11]. All adults aged 18 or above who had spent the previous night in the community were 
eligible to participate in the surveys. Prevalent tuberculosis was ascertained through liquid 
(mycobacterial growth indicator tube [MGIT]) culture of single sputum specimens collected 
on the spot and confirmed as Mycobacterium tuberculosis by 16SrRNA sequencing. Further 
details related to the prevalence survey design have been previously published [10]. Here, 
we distinguished prevalent tuberculosis among adults who reported a history of previous 
tuberculosis treatment (treatment-experienced) from that among adults who reported no 
previous treatment (treatment-naïve). This analysis was approved by the ethics committee of 
Stellenbosch University (Reference number: N04/10/173), and the Institutional Review 
Boards of Partners Healthcare (2014P001719/BWH) and Yale University (1409014625).
All but 15 of the 90,601 adults enrolled in the prevalence surveys provided information 
about history of previous tuberculosis treatment. Among these, 7,362 (8.1%) were 
treatment-experienced, and this proportion varied across the 24 communities between 2.0% 
and 14.9%. Previous treatment was more common in the South African communities, all of 
which had higher estimates of tuberculosis prevalence than the Zambian communities 
(Figure 1a). Treatment-experienced adults were older than treatment-naïve adults (median 
age: 38 vs. 29 years) and more often HIV-positive (45.1% vs. 14.3%).
Among 64,452 adults successfully evaluated for prevalent tuberculosis, 894 (1.39%) 
prevalent tuberculosis cases were detected. The mean prevalence of tuberculosis (weighted 
for numbers of adults evaluated) in the South African communities was 2.34 (95%CI: 2.17 - 
2.52) per 100 adults overall, 3.81 (95%CI: 3.25 - 4.47) per 100 treatment-experienced adults 
and 2.13 (95%CI: 1.96 - 2.31) per 100 treatment-naïve adults. In the Zambian communities, 
it was 0.56 (95%CI: 0.48 - 0.64) per 100 adults overall, 1.01 (95%CI: 0.65 - 1.55) per 100 
treatment-experienced adults and 0.53 (95%CI: 0.46 - 0.62) per 100 treatment-naïve adults. 
Prevalence was higher among treatment-experienced compared to treatment-naïve adults 
across most of the communities (Figure 1b). Stratifying by HIV status suggested that the 
observed difference in tuberculosis prevalence was restricted to HIV-negative adults. In the 
HIV-negative sub-population, TB prevalence was 3.32 (95%CI: 2.57 - 4.27) per 100 
treatment-experienced adults vs. 1.78 (95%CI: 1.57 - 2.02) per 100 treatment-naïve adults in 
the South African, and 0.88 (95%CI: 0.42 - 1.84) per 100 treatment-experienced adults vs. 
0.34 (95%CI: 0.27 - 0.42) per 100 treatment-naïve adults in the Zambian communities. 
Among HIV-positive adults, no significant difference by treatment history was found. TB 
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prevalence among HIV-positive adults overall was 4.82 (95%CI: 4.11 - 5.66) per 100 in the 
South African and 1.61 (95%CI: 1.29 - 2.00) per 100 in the Zambian communities.
Among the 894 prevalent tuberculosis cases, 165 (18.5%) were previously treated. Previous 
treatment was also more common among these prevalent cases in the South African than in 
the Zambian communities (20.7% vs. 10.4%), though the proportion varied considerably and 
exceeded 20% in 9 communities. Treatment-experienced cases were more likely to be 
smear-microscopy positive (49.7% vs. 41.2%) and reported more current cough (43.0% vs. 
34.0%) than treatment-naïve cases.
Our analysis of prevalence survey data from 24 African communities provides key insights 
into an important tuberculosis risk group. Individuals previously treated for tuberculosis 
represent a variably large fraction of the adult population, which is most sizeable in 
communities with the highest tuberculosis burden. Previously treated people may account 
for a considerable fraction of the overall prevalent tuberculosis burden and, among prevelant 
TB cases, those with previous treatment were more likely to be smear-positive and report 
active cough, suggesting substantial risk of onward transmission.
Our study is limited by its cross-sectional design which did not enable us to establish 
underlying causes of recurrent tuberculosis. History of previous treatment was self-reported, 
and no further information about the timing or outcome of previous treatment was available. 
Non-differential loss of specimens, attributable to a failure of positive mycobacterial 
controls in two laboratories, has been discussed previously, but is unlikely to have 
introduced bias into this analysis [10]. Finally, our results probably underestimate 
tuberculosis prevalence in the communities because the surveys did not include individuals 
within health care facilities and other institutions.
The results of our analysis emphasize that targeted interventions to prevent [12] or early 
identify recurrent tuberculosis among previously treated people might be a strategy 
worthwhile to consider for tuberculosis control in settings with a high prevalence of 
tuberculosis and HIV. While ensuring adherence to and the quality of anti-tuberculosis 
treatment within existing control programs remain essential priorities, such efforts may 
reduce relapse but will not directly prevent tuberculosis due to reinfection [2–5]. In areas 
where previously treated individuals are identifiable and reachable, new interventions 
targeted to this particular group could be practical to implement. For example, secondary 
preventive chemotherapy has been shown to substantially reduce the risk of recurrent 
tuberculosis [13, 14]. Active case finding [15] targeted to previously treated people may 
reduce morbidity and transmission as it may shorten the time that recurrent disease remains 
undiagnosed. While such targeted interventions are beneficial to individuals at high risk of 
recurrence, our results suggest that their benefits may extend to the community in settings 
where recurrent tuberculosis contributes to transmission. Future research, in which the costs 
of such targeted interventions and their effects on reducing recurrent tuberculosis and 
associated transmission are better quantified are needed to understand if they can be a cost-
effective element of improved strategies to control tuberculosis in high-burden settings.
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“Take home message”
High TB prevalence among previously treated people suggests potential for targeted 
interventions in high-burden settings
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Figure 1. 
History of previous tuberculosis treatment and prevalent tuberculosis in 24 high tuberculosis 
burden communities in Zambia and the Western Cape Province of South Africa, 2010; Panel 
A: Correlation between the proportion of adults surveyed who reported a history of previous 
treatment and the prevalence of tuberculosis (regardless of treatment history); Panel B: 
Tuberculosis prevalence among treatment-experienced and treatment-naïve adults 
(communities are ordered by the overall tuberculosis prevalence in the communities; no 
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treatment-experienced cases were found in 5 communities; error bars denote 95% 
confidence intervals)
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